Literature DB >> 32927071

Mechanistic insights on clearance and inhibition discordance between liver microsomes and hepatocytes when clearance in liver microsomes is higher than in hepatocytes.

Christopher Keefer1, George Chang1, Anthony Carlo1, Jonathan J Novak1, Michael Banker1, Jackie Carey1, Julie Cianfrogna2, Heather Eng1, Caitlin Jagla1, Nathaniel Johnson1, Rhys Jones2, Samantha Jordan1, Sarah Lazzaro1, JianHua Liu1, R Scott Obach1, Keith Riccardi1, David Tess3, John Umland1, Jillian Racich1, Manthena Varma1, Ravi Visswanathan2, Li Di4.   

Abstract

Human liver microsomes (HLM) and human hepatocytes (HHEP) are two common in vitro systems used in metabolic stability and inhibition studies. The comparison between the assays using the two systems can provide mechanistic insights on the interplay of metabolism, passive permeability and transporters. This study investigated the critical factors impacting the unbound intrinsic clearance (CLint,u) and IC50 of CYP3A inhibition between HLM and HHEP. The HLM/HHEP CLint,u ratio and HHEP/HLM IC50 ratio are inversely correlated to passive permeability, but have no correlation with P-gp efflux ratio. Cofactor-supplemented permeabilized HHEP (MetMax™) collapses the IC50 differences between HHEP and HLM. P-gp inhibitor, encequidar, shows minimal impact on CLint,u and IC50 in HHEP. This is the first study that is able to separately investigate the effects of passive permeability and efflux transport. These data collectively show that passive permeability plays a critical role in metabolism and enzyme inhibition in HHEP, while P-gp efflux has a minor role. This may be due to low functional P-gp activity in suspension HHEP under the assay conditions. Low passive permeability may limit metabolism and enzyme inhibition in HHEP, leading to lower CLint,u and higher IC50 in HHEP compared to HLM. When liver microsomes give higher CLint,u than hepatocytes, microsomes are more predictive of in vivo clearance than hepatocytes.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CYP inhibition; Hepatocytes; IVIVE; Liver microsomes; Metabolism; P-glycoprotein efflux; Passive permeability

Mesh:

Year:  2020        PMID: 32927071     DOI: 10.1016/j.ejps.2020.105541

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  6 in total

1.  In Vitro - in Vivo Extrapolation of Hepatic Clearance in Preclinical Species.

Authors:  David A Tess; Sangwoo Ryu; Li Di
Journal:  Pharm Res       Date:  2022-03-07       Impact factor: 4.200

2.  Designing QSARs for Parameters of High-Throughput Toxicokinetic Models Using Open-Source Descriptors.

Authors:  Daniel E Dawson; Brandall L Ingle; Katherine A Phillips; John W Nichols; John F Wambaugh; Rogelio Tornero-Velez
Journal:  Environ Sci Technol       Date:  2021-04-15       Impact factor: 9.028

3.  Recent developments in in vitro and in vivo models for improved translation of preclinical pharmacokinetics and pharmacodynamics data.

Authors:  Jaydeep Yadav; Mehdi El Hassani; Jasleen Sodhi; Volker M Lauschke; Jessica H Hartman; Laura E Russell
Journal:  Drug Metab Rev       Date:  2021-05-25       Impact factor: 6.984

4.  Influence of Proteome Profiles and Intracellular Drug Exposure on Differences in CYP Activity in Donor-Matched Human Liver Microsomes and Hepatocytes.

Authors:  Christine Wegler; Pär Matsson; Veronica Krogstad; Jozef Urdzik; Hege Christensen; Tommy B Andersson; Per Artursson
Journal:  Mol Pharm       Date:  2021-03-19       Impact factor: 4.939

5.  Study on In Vitro Metabolism and In Vivo Pharmacokinetics of Beauvericin.

Authors:  Yu Yuan; Guangpeng Meng; Yuanbo Li; Chunjie Wu
Journal:  Toxins (Basel)       Date:  2022-07-12       Impact factor: 5.075

Review 6.  Recent advances in the translation of drug metabolism and pharmacokinetics science for drug discovery and development.

Authors:  Yurong Lai; Xiaoyan Chu; Li Di; Wei Gao; Yingying Guo; Xingrong Liu; Chuang Lu; Jialin Mao; Hong Shen; Huaping Tang; Cindy Q Xia; Lei Zhang; Xinxin Ding
Journal:  Acta Pharm Sin B       Date:  2022-03-17       Impact factor: 14.903

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.